National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Search for CCR Trials at NIH


Brain Tumor

A Comparative Study of Pediatric CNS Tumor Activity as Assessed by 18F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI)

NCI-03-C-0278, NCT00070512

Print this page 


Investigator(s):

Katherine E. Warren, M.D.
Principal Investigator
Phone: 301-496-4256
Fax: 301-480-2308
warrenk@mail.nih.gov

Referral Contact(s):

Linda Ellison, R.N.
Research Nurse
Phone: 301-496-8009
Fax: 301-480-8871
ellisonl@mail.nih.gov

Pediatric Oncology
Phone: 301-496-4256
1-877-624-4878 (Toll free)

 

Background:

  • Children with brain tumors are generally followed for response or progression by imaging studies, such as CT or MRI
  • While these imaging studies help delineate the anatomical location and extent of a tumor within the central nervous system, they give no information regarding the biologic or metabolic activity of the lesion
  • Proton Nuclear Magnetic Resonance Spectroscopic Imaging (1H-MRSI) is a non-invasive method of detecting and measuring cellular metabolites in vivo, providing biochemical information in conjunction with the spatial information obtained by MRI
  • Positron Emission Tomography (PET) is a technique that also provides data on metabolic activity of brain lesions
  • A comparison of these two methods in determining a lesion’s metabolic activity has not been reported in children with brain tumors

Objectives:

  • To compare biologic or metabolic activity of brain tumors in pediatric patients as determined by 1H-MRSI and 18F-FDG PET scanning
  • To correlate results of 1H-MRSI and 18F-FDG PET imaging with outcome
  • To use 18F-FDG PET, 1H-MRSI and various MR sequences to evaluate changes over time in primary brain tumors as a result of the natural history of the lesion or therapeutic effects

Key Eligibility Criteria:

  • ≥ 1 years and ≤ 21 years of age
  • Patients must have a brain tumor that is measurable or evaluable on standard MRI or CT

Study Outline:

  • Patients referred to this study will have both 1H-MRSI and 18F-FDG PET imaging performed within 2 weeks of each other at the National Cancer Institute
  • Patients will remain on this study for 5 years or until one of the off-study criteria have been met (whichever comes first)

Additional Information:

  • This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
  • There is no charge for medical care received at NIH Clinical Center.
  • FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, and study outline.
    •
  • PDQ (Physicians Data Query) - provides additional details about this study for health care providers.
    •


Reviewed: 12/14/12
Updated: 8/1/12

Back to Top